Abstract: Antitumor agents LL-D49194.alpha..sub.1, LL-D49194.beta..sub.1, LL-D49194.beta..sub.2, LL-D49194.beta..sub.3, LL-D49194.gamma., LL-D49194.delta., LL-D49194.epsilon., LL-D49194.xi., LL-D49194.eta., LL-D49194.omega., LL-D49194.omega..sub.2 and LL-D49194.omega..sub.3.

Abstract: A process for the preparation of a dicarboxylic acid using a thermophilic croorganism, and the microorganism used. The process involves cultivating a microorganism belonging to the genus Mycobacterium which produces a dicarboxylic acid at high temperatures in a medium to which a substrate selected from among normal paraffins, fatty acids, and their derivatives, each containing 6 to 22 carbon atoms, has been added, so that a dicarboxylic acid containing 6 to 22 carbon atoms is formed and accumulated in the medium, and collecting the dicarboxylic acid.

Abstract: Methods and compositions are provided for expression of polypeptides in transformed bacterial hosts. A novel class of plasmid cloning vehicles includes a DNA sequence coding for the desired polypeptide linked in reading phase with one or more functional fragments derived from an outer membrane protein gene of a gramnegative bacterium. The methods utilize such plasmids to introduce genetic capability into micro-organisms for the production of proteins, such as medically or commercially useful hormones, enzymes, immunogenic proteins, or intermediates therefor.

Abstract: The new streptomyces plasmid p SG 2, having a molecular weight of 9.2 megadaltons, a contour length of 4.58 .mu.m and a molecular length of about 13.8 kilobases, is described, together with its preparation from a culture of "Streptomyces ghanaensis" ATCC 14 672.

Abstract: The invention relates to a new microbiological process for the preparation of clavine alkaloids of the general formula (I), ##STR1## wherein R stands for hydroxymethyl or methyl group, by cultivation of a Claviceps fusiformis strain in liquid submerged culture medium containing sources of carbon, nitrogen, mineral salts and optionally other additives, under aerobic conditions, in which a Claviceps fusiformis variant strain deposited under No. 00211 is used as alkaloid-producing strain. The invention further relates to a biologically pure culture of the Claviceps fusiformis variant strain No. 00211 obtained in a process in which a Claviceps fusiformis strain No. 00164 is grown in a solid culture medium containing sources of carbon, nitrogen, mineral salts and agar as well as an additive promoting the formation of cytochrome P-450, followed by the selective isolation of the new strain No. 00211.

Abstract: A method is provided for preparing L-(+)-.beta.-hydroxyisobutyric acid by fermentation employing microorganisms of the species Pseudomonas aeruginosa and of the genus Protaminobacter such as of the species Protaminobacter alboflavus, and isobutyric acid and/or methacrylic acid and/or derivatives thereof as the substrate.

Abstract: Disclosed is a novel vector, plasmid pCG1, and a process of producing plasmid pCG1 from Corynebacterium glutamicum.

Abstract: Novel Protein A-producing Gram-positive bacterial strains and methods for their preparation are disclosed. Also disclosed are methods for producing Protein A using the novel Gram-positive strains.

Abstract: Disclosed in this invention is a process for the preparation of adenosine-5'-triphosphate by means of fermentation, using an adenosine-5-triphosphate-producing bacterium which assimilates methanol.

Abstract: There are described a number of plasmid vectors suitable for the expression of genetic material, at various levels in yeasts. The plasmids each comprise a yeast selective marker, a yeast replication origin and a yeast promoter positioned relative to a unique restriction site in such a way that expression may be obtained of a polypeptide coding sequence inserted at the restriction site. The promoters used are derived from the 5' region of a gene coding for a yeast glycolytic enzyme e.g. phosphoglycerate kinase (PGK), or from the 5' region of the yeast TRP1 gene. In one Example a plasmid contains a promoter derived from both the 3' and 5' regions of the PGK gene. The replication systems used involve the yeast 2.mu. replication origin or an autonomous replicating sequence (ARS) stabilized with an ARS stabilizing sequence (ASS). The replication systems allow for a choice of high or low copy number per cell. The promoter sequences allow for a choice of high or low expression level.

Abstract: The present invention concerns a new antibiotic substance arbitrarily designated as antibiotic SB 22484, to a process for its production by culturing Streptomyces sp. NRRL 15496 or a producing variant or mutant thereof, and to the use of the new antibiotic substance in the treatment of infectious diseases involving microorganisms susceptible to this antibiotic substance.

Abstract: A new antibiotic substance, which has been named nargenicin C.sub.1, has been isolated from fermentations of a species of the genus Nocardia. Nargenicin C.sub.1 can be used as an antibacterial agent against susceptible bacteria, especially susceptible strains of Staphylococcus aureus.

Abstract: A cloning vector comprises a replication system derived from the pTAR plasmid and capable of stable maintenance in Agrobacterium tumefaciens. By combining the pTAR replication system with a second replication system from a host other than A. tumefaciens, shuttle vectors are obtained which allow manipulation in more than one host. The cloning vectors will usually include selectable markers having restriction enzyme sites which allow identification of recombinant molecules by insertional inactivation. By providing at least a fragment of the T-DNA region from the Ti plasmid, the subject vectors can be used to clone desired DNA fragments and transfer these fragments to the genome of a higher plant.The strain E. coli HB101/puc0400 was deposited on June 7, 1983 at the A.T.C.C. for patent purposes and granted accession no. 39377.

Abstract: A one step method of producing conjugated ursodeoxycholic acids from conjugated lithocholic acids by means of microbial transformation which comprises subjecting the conjugated lithocholic acids to the action of microorganisms which belong to Mortierella and which are capable of producing conjugated ursodeoxycholic acids from conjugated lithocholic acids.

Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.

Abstract: Cultivation of a strain of the microorganism Pseudomonas cepacia which has been deposited in the American Type Culture Collection as A.T.C.C. No. 39277, yields novel antibiotic substances xylocandin A and xylocandin B having activity against yeasts and fungi.

Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.

Abstract: A method for detecting chronic myelogenous leukemia in a human comprising the step of testing a biological sample from a patient to determine the presence of a marker protein (P210) which is characterized as a c-abl protein having tyrosine kinase activity and a molecular weight of approximately 210,000. Antisera which are specific for the P210 protein are disclosed which can be used to precipitate the P210 protein to allow identification by gel electrophoresis or other technique.

Abstract: An E. Coli plasmid SV40 vector recombinant is cloned to a gene of interest and amplified in bacteria. The SV40 vector-gene of interest can be introduced into eukaryotic cells by transformation or transfection and the gene of interest produces its protein product.

Abstract: Promoters associated with expression of specific enzymes in the glycolytic pathway are used for expression of alien DNA, particularly yeast promoters known to provide high enzyme levels of enzymes in the glycolytic pathway are employed for expressing a mammalian protein, such as .alpha..sub.1 -antitrypsin. The promoters include promoters involved in expression of pyruvate kinase, triose phosphate isomerase, phosphoglucose isomerase, phosphoglycerate mutase, hexokinase 1, hexokinase 2, glucokinase, phosphofructokinase, and aldolase, as well as the glycolytic regulation gene. Particularly, the glycolytic regulation gene can be used in conjuction with promoters in the glycolytic pathway for regulated production of desired proteins.